Venous Thromboembolism and Gancer: a Two-Way Clinical Association

• References

• 1 Trousseau A. Phlegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu de Paris. London, New Sydenham Society: 1872: 281-295
• 2 Donati MB, Poggi A. Malignancy and haemostasis. Br J Haematol 1980; 44: 173-182
• 3 Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17: 147-159
• 4 Rickies FR, Levine MN, Edwards RI. Hemostatic alterations in cancer patients. Cancer Metast Rev 1992; 11: 237-248
• 5 Falanga A, Barbui T, Rickies FR, Levine MN. Guidelines for clotting studies in cancer patients. Thromb Haemost. 1993; 70: 540-542
• 6 Kakkar AK, De RuvoN, Chinswangwatanakul V, Tebbutt S, Williamson RCN. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-1005
• 7 Sproul EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 566-585
• 8 Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with acute pulmonary embolism. Ann IntMed 1982; 96: 556-560
• 9 Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparenty healthy patient as a premonitory sign of occult cancer. Cancer 1986; 57: 1846-1849
• 10 Griffin MR, Stanson AW, Brown ML, Hauser MF, O’Fallon WM, Anderson HM, Kazmier FJ, Melton III LJ. Deep venous thrombosis and pulmonary embolism. Arch Intern Med 1987; 147: 1907-1911
• 11 Goldberg RJ, Seneff M, Gore JM, Anderson FA, Greene HL, Wheeler HB, Dalen JE. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987; 147: 251-253
• 12 Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Ma CallejasJ, Martorell A. Occult cancer in patients with deep venous thrombosis: a systematic approach. Cancer 1991; 67: 541-545
• 13 Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, Ten CateJW. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. New Engl J Med 1992; 327: 1128-1133
• 14 Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Mundo MR. Occult cancer in patients with acute pulmonary embolism. Chest 1993; 103: 816-819
• 15 Nordstrom M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994; 308: 891-894
• 16 Naschitz JE, Yeshurun D, Eldar S, Lev LM. Diagnosis of cancer-associated vascular disorders. Cancer 1996; 77: 1759-1767
• 17 Bastounis EA, Karayiannakis AJ, Maiiri Gg, Alexiou D, Papalambros L. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Int Med 1996; 239: 153-156
• 18 Cornuz J, Pearson SD, Creager M, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996; 125: 785-793
• 19 Prins MH, Lensing AWA, Hirsh J. Idiopathic deep venous thrombosis. Is a search for malignant disease justified?. Arch Intern Med 1994; 154: 1310-1315
• 20 Clagett JP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227-240
• 21 Shen VS, Poliak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J 1980; 73: 841-843
• 22 Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep vein thrombosis after major gynecological surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonw 1974; 08: 311-316
• 23 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127: 310-313
• 24 Falanga A, Ofosu FA, Cortellazzo S, Delaini F, Consonni R, Caccia R, Longatti S, Maran D, Rodeghiero F, Pogliani E, Marassi A, D’Angelo A, Barbui T. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993; 85: 745-750
• 25 Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108: 312-334
• 26 Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Buck nall, Stevens J, Port eous. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease?. A double-blind, randomised, multicenter comparison. Thromb Haemost 1993; 70: 562-567
• 27 Godwin J. Use of low molecular weight heparins in malignancy-related thromboembolic disorders: a clinical review. Clin Appl Thromb/Hemost 1996; 02: 28-34
• 28 Danis J, Bergqvist D. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2,500 versus 5,000 anti Xa units in 2070 patients. Br J Surg 1995; 82: 1283-1284
• 29 Bergqvist D. Low molecular weight heparin (enoxaparin) as thromboprophylaxis in cancer surgery. Haemostasis 1996; 26 S (03) 01
• 30 Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De pauwS. The thrombogenic effect of anti-cancer drug therapy in women with stage II breast cancer. New Engl J Med 1988; 318: 404-407
• 31 Saphner T, Tomey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 09: 286-294
• 32 Goodnough LT, Saito H, Manni A, Jones PH, pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer 1984; 54: 1264-1268
• 33 Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard K, Stewart D, Goodwin P. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889
• 34 Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 1983; 52: 1586-1589
• 35 Bern MM, Bothe Jr A, Bistrian B, Champagne CD, Keane MS, Blackburn GL. Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery 1986; 99: 216-221
• 36 Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med 1990; 112: 423-428
• 37 Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices. Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-253
• 38 Zacharski LR, henderson WG, rorman WB. et al Bleeding complications from warfarin anticoagulation in patients with malignancy. J Med 1985; 16: 535-561
• 39 Chahinian AP, Ware JH, Zim mer. Update on anticoagulation carcinoma of the lung (SCCL). Proc Am Clin Oncol 1985; 04: 191
• 40 Prandoni P, Lesing AWA, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten CateJW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445
• 41 Hull RD, Raskob GL, Pineo GF. et al Subcutaneous low-molecular-weight heparin compared with intravenous heparin in the treatment of proximal-vein thrombosis. New Eng J Med 1992; 326: 975-982
• 42 Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339: 1476